Development of a Pan-Proteome Multi-Epitope Vaccine Candidate Against Nipah Virus Using Reverse Vaccinology and Immunoinformatics Approaches

VC033_V6_BD_L03, a consensus-derived pan-proteome multi-epitope Nipah virus vaccine construct, predicts 99.78% worldwide and 99.96% South Asia HLA coverage.

• Why it matters: Nipah virus remains a high-consequence zoonotic threat with no licensed human vaccine, creating a need for broadly immunogenic candidates spanning viral proteins.
• What they did: Using 842 quality-filtered sequences from all nine NiV proteins, the team generated consensus fragments, screened CTL/T-helper/B-cell epitopes, built 60 constructs, then applied docking, 100-ns molecular dynamics, MM/GBSA, and immune-simulation plus expression optimization.
• The result: The lead construct shows ClusPro docking to human TLR3 (1ZIW) with a score of -1624.8, MM/GBSA mean interaction energy of -20.52, 15.42 kcal/mol, and a 1,539-bp codon-optimized sequence compatible with virtual cloning into pET-28a(+).

AI summary of the abstract · may contain errors · not medical advice · read the paper.